CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Consensus Target Price from Brokerages

CytomX Therapeutics, Inc. (NASDAQ:CTMX) has been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $5.77.

Separately, HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a research note on Tuesday, January 7th.

Hedge Funds Weigh In On CytomX Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Traphagen Investment Advisors LLC bought a new stake in CytomX Therapeutics during the 4th quarter valued at $31,000. US Bancorp DE bought a new stake in shares of CytomX Therapeutics during the third quarter valued at about $40,000. XTX Topco Ltd lifted its holdings in CytomX Therapeutics by 382.6% in the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 48,033 shares during the period. Forefront Analytics LLC grew its position in CytomX Therapeutics by 206.7% in the 2nd quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 43,176 shares in the last quarter. Finally, Cubist Systematic Strategies LLC increased its stake in CytomX Therapeutics by 96.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 40,309 shares during the period. 67.77% of the stock is currently owned by institutional investors and hedge funds.

CytomX Therapeutics Stock Performance

Shares of NASDAQ:CTMX opened at $0.84 on Tuesday. CytomX Therapeutics has a 1-year low of $0.79 and a 1-year high of $5.85. The company’s fifty day moving average is $1.04 and its two-hundred day moving average is $1.15. The stock has a market capitalization of $65.74 million, a price-to-earnings ratio of 4.94 and a beta of 1.03.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.23. The firm had revenue of $33.43 million for the quarter, compared to analysts’ expectations of $18.92 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. During the same quarter last year, the company posted $0.04 earnings per share. Sell-side analysts expect that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.